Antibody Purification Patents: Who Leads, Where the Gaps Are 2026
- 55.6% concentration. The top 5 assignees hold 160 of 288 records in scope, a tight cluster around Protein A chromatography and host-cell-protein removal.
- Filing is climbing, not cooling. From 2021 to 2024 — the last complete year in this dataset — filings rose from 12 to 20, up 67% over that span.
- One family anchors the citation graph. US6870034B2 draws 263 citations, more than double the next most-cited record, and still shapes how later elution and wash-buffer claims are drafted.
Filing growth compares 2021 (12 records) with 2024 (20) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 288 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review maps 288 published records filed against antibody purification process development between 2015 and mid-2026, drawn from filings that combine Protein A chromatography or antibody purification process language with claim terms covering resin binding capacity, host cell protein clearance, viral clearance, buffer consumption, continuous capture and elution pH. The scope is narrow by design: it isolates process-engineering claims around the capture and polishing steps rather than the antibody molecules themselves.
Because publication trails filing by roughly 18 months, the last one to two years in any trend undercount real filing activity. Family-level counts, used throughout, are the fairer comparison across assignees since they neutralise continuation practice and multi-jurisdiction refiling of the same invention.
Filing trends and technology composition
Two views of the same 288 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend: momentum builds after 2021
Filings peaked at 26 in 2018, cooled, then rebuilt: 2021 to 2024 rose from 12 to 20 records, a 67% increase over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a slowdown.
Technology composition: concentrated in peptide chemistry, spread across separation and biology
C07K (peptides and proteins) touches 93.1% of the 288 records, confirming this is fundamentally protein-chemistry claim territory. B01D (separation processes) at 17.4% and B01J (catalysis/physical processes) at 6.9% mark the hardware and resin side; A61K (medicinal preparations) at 13.5% and C12N/C12P (microbial and fermentation biology) at 8.3% and 6.9% show where purification claims intersect with upstream biology and formulation.
Shares are the percentage of the 288 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Antibody Purification Process Development with Eureka
This page is one run against one query. Ask Eureka your own question about antibody purification process development and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping this field
US20160108084A1 — Purification Of Recombinantly Produced Polypeptides
Described herein is a method for separating a recombinantly produced polypeptide from host cell protein. The method includes a step of loading a clarified cell culture supernatant that includes the recombinantly produced polypeptide and the HCP onto a Protein A chromatography column and washing the Protein A chromatography column with a wash buffer comprising a fatty acid having a chain length of at least about 6 carbons, or a fatty acid salt thereof, to remove HCP and then recovering the recombinantly produced polypeptide.Filed by MedImmune Limited, published 2016-04-21. Selected here as representative of the wash-buffer chemistry approach to host-cell-protein clearance that recurs across the dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6870034B2 | Protein purification | 263 |
| 2 | US20030153735A1 | Protein purification | 144 |
| 3 | US20160024147A1 | Purification Platform for Bispecific Antibodies | 121 |
| 4 | US20140154270A1 | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography | 99 |
| 5 | WO2003066662A2 | Protein purification | 70 |
| 6 | US20120208986A1 | Use of mixed mode chromatography for the capture and purification of basic antibody products | 57 |
| 7 | WO2009138484A2 | Antibody purification process | 56 |
| 8 | WO2011049798A1 | Use of mixed mode chromatography for the capture and purification of basic antibody products | 51 |
| 9 | WO2014186350A1 | Purification of recombinantly produced polypeptides | 47 |
| 10 | WO2007109163A2 | Wash buffer and method of using | 39 |
Ranked by citation count within this searched corpus; older filings accumulate citations by tenure, so treat this as a signal of influence on later drafting, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three read-outs from the concentration, citation and technology figures above, framed for teams deciding where to file or partner next.
The core Protein A claim space is crowded at the top
With 160 of 288 records held by five assignees, new filings aimed squarely at core Protein A capture chemistry are entering dense prior art. Differentiation is more likely to succeed in adjacent process steps than in the core binding chemistry itself.
Activity is rebuilding after the 2018 peak, not fading
The 2018 peak of 26 filings was followed by a lull, but 2021-2024 shows renewed growth of 67%. Because 2025-2026 data is still filling in under normal publication lag, current filing intent is understated, not falling.
One foundational family still anchors drafting
US6870034B2 draws more than double the citations of the next-most-cited record, meaning claim language around it has been studied and designed around repeatedly. New filings referencing elution or wash-step chemistry should expect examiners to cite it.
Hardware and resin claims are a smaller, less contested slice
While C07K peptide chemistry dominates at 93.1% of records, separation-process claims under B01D sit at a comparatively modest 17.4%, and catalysis-adjacent B01J at 6.9%. That gap suggests more room in process-hardware claims than in the underlying chemistry.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to antibody purification process development, with the prior art for and against each one.
Who is filing, and where they are pulling back
The ranked leaders in this dataset show a clear cluster at the top and matching co-filing relationships, but recent-year momentum data suggests most of that cluster has slowed its own filing pace even as the field overall grows.
A single filer leads by a wide margin
The top-ranked assignee holds 39 records against a fifth-place figure of 23 and a tenth-place figure of 11 — a steep drop-off that marks this as a leader-plus-cluster field rather than an evenly split one.
Corporate affiliation drives the strongest co-filing pairs
The strongest co-assignee pairs in this dataset link corporate parent-subsidiary structures, most notably a pairing recording 15 shared records — consistent with in-house R&D units filing jointly rather than arm's-length collaboration.
Leaders show zero recent-year filings, consistent with publication lag
Several of the highest-ranked assignees, including the second-ranked filer, show zero records in the latest year and one records a -100% year-on-year change. Given the roughly 18-month publication lag, this reads as pipeline still filling in rather than genuine exit from the field.
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech Inc | 0 | — |
| Genzyme Corp | 0 | -100% |
| Regeneron Pharmaceuticals Inc | 0 | — |
| F. Hoffmann-La Roche AG | 0 | — |
| Seagen Inc | 0 | — |
| EMD Millipore Corp | 0 | — |
| MedImmune LLC | 0 | — |
| MedImmune Limited | 0 | — |
Where to take this analysis
The figures above describe the shape of the field. Turning that into a filing or freedom-to-operate decision means going deeper into specific claim sets and specific competitors.
Map claims against your own process steps
Overlay your capture, wash and elution parameters against the claim language held by the leading assignees to find where your process sits inside or outside existing claim boundaries.
Explore in Patsnap Eureka →Track the assignees showing renewed filing
Filing growth from 2021 to 2024 was not evenly spread; identifying which specific assignees are behind that growth narrows down who to watch for freedom-to-operate risk going forward.
Run an assignee deep-dive in Patsnap Eureka →Common questions on antibody purification patents
The dataset's ranked leader holds 39 of 288 records, well ahead of the fifth-place assignee at 23 and tenth place at 11. The top five assignees combined hold 160 records, or 55.6% of all 288 records in scope, so filing activity is concentrated rather than evenly spread across the 74 ranked companies. That concentration is strongest around core Protein A chromatography claims, with a longer tail of single- or few-filing entrants behind the leaders.
Yes, based on the last complete filing years in this dataset: filings rose from 12 in 2021 to 20 in 2024, a 67% increase over that span, after an earlier peak of 26 filings in 2018. Records from 2025 and 2026 appear lower only because publication lags filing by roughly 18 months, not because filing has slowed. Anyone reading the most recent one to two years as a decline is misreading a data artifact rather than a real trend.
US6870034B2, titled Protein purification, is the most-cited record in this dataset at 263 citations, more than double the next most-cited filing. Its heavy citation count means later filings on elution and wash-step chemistry have repeatedly had to design around or reference it during prosecution. Treat its citation weight as evidence of its influence on how claims in this space have been drafted, not as a current measure of commercial dominance.
The technology composition data shows claim density concentrated heavily in C07K peptide and protein chemistry, at 93.1% of the 288 records, while separation-process claims under B01D sit at a comparatively lower 17.4% and catalysis-related B01J claims at 6.9%. That gap points to more open claim space in process-hardware and separation-engineering approaches, such as continuous capture integration or buffer-consumption reduction, than in the underlying binding chemistry itself. Confirming true white space still requires checking specific claim language, not just IPC class density.
US20160108084A1, filed by MedImmune Limited and published in 2016, claims a method of loading clarified cell culture supernatant onto a Protein A column and washing it with a buffer containing a fatty acid or fatty acid salt with a chain length of at least about 6 carbons to remove host cell protein. That specific combination — Protein A capture plus a defined-chain-length fatty acid wash step for HCP clearance — is the practical boundary this filing sets. A process using a different wash-buffer chemistry, or removing HCP through a different mechanism such as a secondary polishing resin, would sit outside its literal claim scope, though a full freedom-to-operate check should read the granted claims directly rather than relying on the abstract.
Research Antibody Purification Process Development in depth with Eureka
Go past this page: query the whole antibody purification process development corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.